Shots:
- ImmunityBio has reported P-II (QUILT-3.055) trial data assessing Anktiva (nogapendekin alfa inbakicept-pmln) + checkpoint inhibitor immunotherapy (CPI) in CPI-resistant advanced NSCLC
- Among 86 pts (51% 2L, 49% 3L+), mOS was 14.3mos. (23 alive at Dec 2025); 69/86 achieving ALC ≥1,200 had mOS of 15.8 vs 11.5mos. in non-achievers, while baseline ALC ≥1,200 & mean ≥1,500 (n=44) linked to mOS of 21.1mos.; 60% (25/42) pts had reversed lymphopenia at ≥1 timepoint; results presented at WCLC’25
- Anktiva is also being evaluated in the ongoing P-III (ResQ201A) trial assessing it in combination with tislelizumab vs docetaxel as a 2L treatment of NSCLC pts who have progressed after all standard therapies, incl. CPI
Ref: ImmunityBio | Image: ImmunityBio | Press Release
Related News:- ImmunityBio’s Anktiva + BCG Receives the MHRA’s Approval for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
